Chamber-specific human iPSC-derived cardiomyocytes for disease modeling and safety

The MyoMax™ Maturation Media Brochure from Axol Bioscience introduces a breakthrough solution for improving the maturity of human iPSC-derived cardiomyocytes. Cardiotoxicity remains a leading cause of drug development failure, and immature cardiomyocyte models often limit translational relevance. MyoMax™ addresses this challenge by promoting adult-like features in cardiomyocytes, enabling more robust and predictive in vitro cardiac assays.

Key benefits include:

• Enhanced morphology: Rod-shaped cells with improved sarcomere alignment
• Electrophysiological improvements: Reduced beat rate, increased conduction velocity, and shortened field potential duration
• Metabolic shift: Transition from glucose to fatty acid metabolism
• Upregulation of maturity markers: Increased expression of KCNJ2 (Kir2.1 channel)

Validated using Axion Maestro Pro MEA systems, MyoMax™ delivers measurable improvements in cardiac function within 14 days. It supports applications in cardiotoxicity screening, disease modeling, and drug safety assessment.

Featured Axol Products:

• MyoMax™ Maturation Media (ax2550)
• axoCells™ Ventricular Cardiomyocytes (ax2508 / ax2500)